Previous 10 | Next 10 |
home / stock / bayry / bayry news
100s of companies run trials in Ukraine; some of them will face delays. In the long term, Ukraine may cease to be a favored location for clinical trials. However, neither Russia nor Ukraine are drug manufacturing hubs, and market exposure is minimal. For further details see:...
In light of the UK government's "Global Britain" agenda, the focus on striking new free trade agreements with major global economies is a key priority for the current UK administration in 2022. Developments in sustainable AgriTech, crucial to Brazil's agricultural revolution, could ho...
Inflation concerns have started to affect market sentiment, but it is highly uncertain if that will lead to a real market correction or just some short-term dips. I am continuing my monthly investment plans while still awaiting a real market correction or possibly a real crash once ma...
Bayer (OTCPK:BAYRY -1.2%) said it declared force majeure over supply chain issues on the manufacture of glyphosate products in the U.S., as a supplier of a raw ingredient needed to produce the herbicide has encountered technical problems which will hurt Bayer's short-term production. "A suppl...
Demand for fresh water is outrunning supply as the result of aquifer and reservoir depletion; farmers are having to cut back. At the same time, crops are coming under stress as the result of climate change / global warming and sustained droughts. For growth, value, and income, inv...
The German drugmaker, Bayer (OTCPK:BAYRY) (OTCPK:BAYZF), has appointed Christine Roth as the new head of the Oncology Strategic Business Unit, a part of its pharma division, effective March 01. Formerly the senior vice president, global oncology therapy at GlaxoSmithKline (NYSE:GSK), Roth wil...
The following slide deck was published by Bayer Aktiengesellschaft in conjunction with this event. For further details see: Bayer Aktiengesellschaft (BAYRY) Presents At J.P. Morgan Healthcare Conference
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Despite the first months of the quarter favoring growth, ...
Bayer AG operates in markets with a high potential for growth while occupying a leading position. The company suffered a severe blow due to the purchase of Monsanto and the lawsuits that followed. Considering its financial statements and forecasts, Bayer is fairly valued at the mo...
Recursion Pharma is hoping to revolutionize drug discovery with its Recursion OS technology; potential to improve drug discovery and processing capabilities. Recent deal with Roche brought in an upfront payment of $150 million, with potential to earn up to $300 million for each of the...
News, Short Squeeze, Breakout and More Instantly...
Bayer AG ADR Company Name:
BAYRY Stock Symbol:
OTCMKTS Market:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...